Table 1 Clinical characteristics and univariate Cox regression of overall survival and immune level grouping results of CM patients in the training set.

From: A novel prognostic model for cutaneous melanoma based on an immune-related gene signature and clinical variables

Clinical variables

Training set (n = 291)

Univariate Cox regression

Immune level groups

p-value

HR (95% CI)

p-value

Immunity-H (n = 98)

Immunity-M (n = 82)

Immunity-L (n = 111)

Age at initial diagnosis (years, mean ± SD)

57.33 ± 16.35

1.025 (1.014–1.036)

 < 0.001

56.67 ± 16.08

58.62 ± 15.12

56.96 ± 17.51

0.696

Gender (n, %)

 

0.868 (0.610–1.236)

0.432

   

0.070

Male

181 (62.20)

  

53 (53.06)

54 (65.85)

75 (67.57)

 

Female

110 (37.80)

  

46 (46.94)

28 (34.15)

36 (32.43)

 

Race (n, %)c

 

1.331 (0.714–2.481)

0.369

   

0.960

White

275 (97.17)

  

93 (96.88)

77 (97.47)

104 (97.20)

 

Asian

7 (2.48)

  

2 (2.08)

2 (2.53)

3 (2.80)

 

Black or African American

1 (0.35)

  

1 (1.04)

0 (0.00)

0 (0.00)

 

Not reported

8

      

Pathologic-M

 

1.604 (0.745–3.456)

0.227

   

0.115

M0

253 (92.67)

  

89 (96.74)

70 (88.61)

94 (93.07)

 

M1

20 (7.33)

  

3 (3.26)

9 (11.39)

7 (6.93)

 

Not reported

19

      

Pathologic-N

 

1.293 (1.099–1.522)

0.002

   

0.260

N0

148 (56.92)

  

49 (55.68)

42 (56.00)

57 (58.76)

 

N1

45 (17.32)

  

11 (12.50)

14 (18.67)

20 (20.62)

 

N2

27 (10.38)

  

10 (11.36)

10 (13.33)

7 (7.22)

 

N3

40 (15.38)

  

18 (20.45)

9 (12.00)

13 (13.40)

 

NX

17

      

Not reported

14

      

Pathologic-T

 

1.455 (1.223–1.732)

 < 0.001

   

0.001

T0

14 (5.88)

  

8 (10.39)

3 (4.17)

3 (3.37)

 

T1

29 (12.18)

  

17 (22.08)

8 (11.11)

4 (4.49)

 

T2

47 (19.75)

  

15 (19.48)

18 (25.00)

14 (15.73)

 

T3

55 (23.11)

  

17 (22.08)

13 (18.06)

25 (28.09)

 

T4

93 (39.08)

  

20 (25.97)

30 (41.67)

43 (48.31)

 

Tis

6

      

TX

27

      

Not reported

20

      

Primary neoplasm (n, %)

 

0.740 (0.375–1.460)

0.385

   

0.134

Yes

261 (89.69)

  

83 (84.69)

76 (92.68)

102 (91.89)

 

No

30 (10.31)

  

15 (15.31)

6 (7.32)

9 (8.11)

 

Previous systemic treatment

 

1.073 (0.627–1.837)

0.797

   

0.010

Yes

22 (7.56)

  

3 (3.06)

4 (4.88)

15 (13.51)

 

No

269 (92.44)

  

95 (96.94)

78 (95.12)

96 (86.49)

 

Primary radiotherapy

 

1.271 (0.403–4.003)

0.682

   

0.353

Yes

8 (3.15)

  

1 (1.25)

2 (2.70)

5 (5.00)

 

No

246 (96.85)

  

79 (98.75)

72 (97.30)

95 (95.00)

 

Not reported

37

      

Tumor locationa

 

0.916 (0.803–1.044)

0.189

   

 < 0.001

Distant metastasis

46 (15.97)

  

6 (6.19)

10 (12.20)

30 (27.52)

 

Primary tumor

59 (20.49)

  

12 (12.37)

20 (24.39)

27 (24.77)

 

Regional cutaneous or subcutaneous tissueb

44 (15.28)

  

10 (10.31)

18 (21.95)

16 (14.68)

 

Regional lymph node

139 (48.26)

  

69 (71.13)

34 (41.46)

36 (33.03)

 

Not reported

3

      

Tumor stage (n, %)

 

1.344 (1.109–1.630)

0.003

   

0.499

0

6 (2.27)

  

2 (2.33)

0 (0.00)

4 (3.96)

 

I

49 + 3 (19.70)

  

25 (29.07)

16 (20.78)

11 (10.89)

 

II

81 + 2 (31.44)

  

18 (20.93)

24 (31.17)

41 (40.59)

 

III

105 (39.77)

  

38 (44.19)

29 (37.66)

38 (37.62)

 

IV

18 (6.82)

  

3 (3.49)

8 (10.39)

7 (6.93)

 

I/II

5c

      

Not reported

27

      
  1. HR hazard ratio, 95% CI 95% confidence interval, SD standard deviation.
  2. aDummy variable.
  3. bIncludes satellite and in-transit metastasis.
  4. cThe 5 CM patients were randomly assigned to I (n = 3) or II (n = 2).
Back to article page